未登录

K

Kin Man Au

university of north carolina

H指数:16

被引数:1,019

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiple sclerosis treatments a review of current biomedical engineering approaches

多发性硬化症治疗当前生物医学工程方法的综述

IF12.9

2025-02-010

PRE

Intratumoral Injectable Redox-Responsive Immune Niche Improves the Abscopal Effect in Radiotherapy

ADVANCED MATERIALS

IF26.8

2024-11-060

PRE

An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis (Dec, 10.1038/s41551-023-01136-9, 2023)

NATURE BIOMEDICAL ENGINEERING

IF26.6

2024-06-110

OA

Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma (vol 12, pg 1544, 2018)

IF16

2024-05-280

OA

Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigen-Specific Therapy for Experimental Autoimmune Encephalomyelitis (vol 34, 2107392, 2022)

ADVANCED MATERIALS

IF26.8

2024-05-270

OAAI

Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles (vol 9, pg 8976, 2015)

IF16

2024-05-140

OA

High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles (vol 5, pg 122, 2019)

ACS CENTRAL SCIENCE

IF10.4

2024-05-080

OAAI

Ligand-independent targeting of tumor cells for antibody-dependent cellmediated cytotoxicity

CANCER RESEARCH

IF16.6

2024-03-220

PRE

An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis

NATURE BIOMEDICAL ENGINEERING

IF26.6

2023-12-044

OA

Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigen-Specific Therapy for Experimental Autoimmune Encephalomyelitis

ADVANCED MATERIALS

IF26.8

2021-12-1311

OA

In Vivo Bioengineering of Beta Cells with Immune Checkpoint Ligand as a Treatment for Early-Onset Type 1 Diabetes Mellitus

含免疫检查点配体的 β 细胞体内生物工程治疗早发1型糖尿病

IF16

2021-11-2917

PREAI

Immune Checkpoint-Bioengineered Beta Cell Vaccine Reverses Early-Onset Type 1 Diabetes

免疫检查点-生物工程 β 细胞疫苗逆转早发1型糖尿病

ADVANCED MATERIALS

IF26.8

2021-05-0817

OA

Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models

ACTA BIOMATERIALIA

IF9.6

2021-04-0146

OAAI

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy

SCIENCE ADVANCES

IF12.5

2020-07-0374

OAAI

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma

SCIENCE ADVANCES

IF12.5

2020-04-0341

OAAI

High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles

ACS CENTRAL SCIENCE

IF10.4

2018-12-2632

OAAI

Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models

IF12.9

2018-07-0172

OAAI

Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma

定制的预靶向纳米放射免疫疗法治疗非霍奇金淋巴瘤

IF16

2018-01-2642

OAAI

Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models

JOURNAL OF MATERIALS CHEMISTRY B

IF5.7

2017-01-0150

OAAI